Sphera Funds Management’s Milestone Pharmaceuticals MIST Stock Holding History

Sphera Funds Management’s Portfolio MIST Stock Details MIST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-820,000	Closed	-$1.64M	–	119
2025 Q3	$1.64M	Buy	+820,000	New	+$1.44M	0.35%	80
2020 Q2	–	Sell	-67,992	Closed	-$125K	–	100
2020 Q1	$125K	Buy	+67,992	New	+$1.18M	0.02%	77

Other funds holding MIST

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Sphera Funds Management's MIST Position: Q4 2025 in Review

Sphera Funds Management sold out of Milestone Pharmaceuticals (MIST) in Q4 2025, closing a stake of 820,000 shares — an estimated $1.64M sold.

Sphera Funds Management first reported a position in MIST in Q1 2020 and held it in 2 quarters. The position peaked at $1.64M in Q3 2025. 79 funds tracked by Wall St. Rank hold MIST as of Q4 2025.

Sphera Funds Management reported no remaining Milestone Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Sphera Funds Management sold 820,000 Milestone Pharmaceuticals shares in Q4 2025, an estimated $1.64M.
Sphera Funds Management first reported a position in Milestone Pharmaceuticals in Q1 2020 and held it in 2 quarters.
Sphera Funds Management's Milestone Pharmaceuticals position peaked at $1.64M in Q3 2025.
79 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q4 2025.

Based on Sphera Funds Management's 13F filing for Q4 2025, filed 17 Feb 2026.